Literature DB >> 19571806

The animal rule and emerging infections: the role of clinical pharmacology in determining an effective dose.

K L Bergman1.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19571806     DOI： 10.1038/clpt.2009.106

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  6 in total

Review 1.  Chemical inhibitors of the type three secretion system: disarming bacterial pathogens.

Authors:  Miles C Duncan; Roger G Linington; Victoria Auerbuch
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

2.  Efficacy and safety of AVP-21D9, an anthrax monoclonal antibody, in animal models and humans.

Authors:  Nina V Malkevich; Robert J Hopkins; Edward Bernton; Gabriel T Meister; Eric M Vela; George Atiee; Virginia Johnson; Gary S Nabors; Ronald T Aimes; Boris Ionin; Mario H Skiadopoulos
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

3.  Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax.

Authors:  Nutan Mytle; Robert J Hopkins; Nina V Malkevich; Subhendu Basu; Gabriel T Meister; Daniel C Sanford; Jason E Comer; Kristopher E Van Zandt; Mohamed Al-Ibrahim; William G Kramer; Cris Howard; Nancy Daczkowski; Ajoy C Chakrabarti; Boris Ionin; Gary S Nabors; Mario H Skiadopoulos
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

4.  Modeling and simulation in dose determination for biodefense products approved under the FDA animal rule.

Authors:  Kimberly L Bergman; K Krudys; S K Seo; J Florian
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-03-15       Impact factor: 2.410

5.  Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans.

Authors:  Janet M Leeds; Frederique Fenneteau; Nathalie H Gosselin; Mohamad-Samer Mouksassi; Nastya Kassir; J F Marier; Yali Chen; Doug Grosenbach; Annie E Frimm; Kady M Honeychurch; Jarasvech Chinsangaram; Shanthakumar R Tyavanagimatt; Dennis E Hruby; Robert Jordan
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.938

Review 6.  BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease.

Authors:  Raymond Taylor; Pravin Kotian; Travis Warren; Rekha Panchal; Sina Bavari; Justin Julander; Sylvia Dobo; Angela Rose; Yahya El-Kattan; Brian Taubenheim; Yarlagadda Babu; William P Sheridan
Journal:  J Infect Public Health       Date:  2016-04-16       Impact factor: 3.718
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.